Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WEF26: Saudi Arabia Leads New Global Push to Protect Coral Reefs, Unlock AI Potential22.1.2026 06:52:00 EET | Press release
The Saudi delegation to the World Economic Forum (WEF) Annual Meeting 2026 today observed a series of announcements aimed at addressing urgent global challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121465066/en/ Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced at the World Economic Forum Annual Meeting that Saudi Arabia will host the first Global Coral Reef Summit in 2026 (Photo: AETOSWire) Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced that Saudi Arabia will host the first Global Coral Reef Summit in 2026, bringing together global leaders, scientists, and investors to drive solutions for the protection and recovery of coral reef ecosystems. The summit will address key challenges and policy and regulatory gaps, develop science-based sol
BitGo Holdings Announces Pricing of Initial Public Offering22.1.2026 04:38:00 EET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closin
Kioxia Selected in Clarivate Top 100 Global Innovators 202622.1.2026 03:30:00 EET | Press release
Kioxia Corporation has been named a Clarivate Top 100 Global Innovators 2026, an award given to the most innovative global companies by Clarivate Plc. This is the fifth time Kioxia has received this prestigious award in recognition of its accomplishment in intellectual property. The Clarivate Top 100 Global Innovators 2026 Awards were presented to the world’s most innovative companies and organizations, based on Clarivate’s proprietary analysis of intellectual property and patent trends. The methodology uses a model that measures innovation and focuses on consistent high performance and scale in innovativeness, where all ideas compete equally. Based on its mission of “uplifting the world with ‘memory,’” Kioxia will cultivate a new era of flash memory with its innovative technology to promote research and technology development that supports the increasing adoption of AI and the digital society of the future. Kioxia continues to protect and effectively utilize its intellectual property
Access Advance Closes 2025 with Record Quarter: Eight Major Licensees, 100% Renewal Rate, Litigations Resolved22.1.2026 03:00:00 EET | Press release
Access Advance LLC today announced the conclusion of an exceptional fourth quarter, with growth in all three main patent pools highlighted by the addition of eight major Licensees, a 100% renewal rate among HEVC Advance Licensees in good standing, and the resolution of multiple Licensor enforcement actions through pool licenses. The HEVC Advance Patent Pool welcomed 29 new Licensees, an 8% increase in total Licensees in just three months. The VVC Advance Patent Pool grew 40% with the signing of eight new Licensees, while the Advance VDP Pool added both a new Licensor and the first U.S.-based Licensee. Among the new Licensees joining Access Advance's programs were Hisense, Mercedes-Benz AG, Roku, Skyworth, Transsion, and Xiaomi in HEVC Advance; OPPO, vivo and Xiaomi in VVC Advance, and Roku in the VDP Pool. The quarter also saw the resolution of multiple Licensor-initiated litigations through licensing, with Hisense, Roku, and Transsion joining the HEVC Advance Patent Pool. Roku also be
IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 202621.1.2026 23:15:00 EET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom